COPENHAGEN — The battle over the world’s most popular weight-loss drugs has intensified, with Novo Nordisk filing a patent infringement lawsuit against telehealth firm Hims & Hers. The case targets Hims’ attempt to sell “compounded” versions of Novo’s blockbuster drug Wegovy and comes just 48 hours after Hims shut down its $49-a-month pill following a stern warning from federal regulators.
The dispute marks a tipping point for the pharmaceutical industry. For months, smaller players have exploited legal grey areas to sell cheaper, custom-mixed versions of GLP-1 weight-loss drugs while official supplies were limited. Now, Novo Nordisk, backed by U.S. regulators, is moving to stop what it describes as illegal mass compounding of patented medicines.
A Chaotic Weekend for Hims & Hers
The drama began last Thursday when Hims announced plans to sell a semaglutide pill, the same active ingredient as Wegovy, for just $49, massively undercutting Novo’s official price of around $149 for self-paying patients. By Saturday, the company reversed course, saying it would halt the treatment after “constructive conversations” with industry stakeholders.
That abrupt U-turn followed an unusually direct warning from the FDA. Commissioner Dr Marty Makary said the agency would take decisive action against companies mass-marketing unapproved drugs. Regulators argue that compounded versions have not been adequately tested for safety or purity. In its lawsuit, Novo Nordisk alleged that some knockoff products contained impurity levels as high as 86%, posing serious risks to patients.
TrumpRx and the New Drug Deals
Even as it fights copycats in court, Novo Nordisk is working with the U.S. government to make its official drugs more affordable. Last year, Novo and rival Eli Lilly struck landmark agreements with President Donald Trump to list their products on the TrumpRx platform. Under the program, patients can access official Wegovy and Ozempic for about $199 to $350 per month, down from roughly $1,300.
By offering these “Most Favoured Nation” prices, drugmakers hope to draw consumers away from compounding pharmacies. The Trump administration has also granted Novo Nordisk a three-year tariff reprieve in exchange for a $10 billion investment in U.S. manufacturing, aiming to boost supply and reduce the appeal of unapproved alternatives.
What’s Next for the Weight-Loss Market?
The lawsuit against Hims marks the first time Novo Nordisk has used patent litigation to directly challenge a compounding firm in the U.S. Analysts say it signals an all-out crackdown on the sector. A victory for Novo could set a precedent that prevents telehealth companies from selling versions of patented GLP-1 drugs, even during future shortages.
Markets are already reacting. Novo’s shares rebounded 5% to 8% on Monday, while Hims’ stock sank 20%, wiping out millions in market value. With Eli Lilly set to launch its own official weight-loss pill in April, the industry appears to be pivoting away from copycats and back toward patent-holding pharmaceutical giants.
Key Highlights
- Novo Nordisk sued Hims & Hers for patent infringement on Monday, Feb. 9.
- Hims pulled its $49 weight-loss pill after the FDA threatened legal action.
- Hims shares plunged 20%, while Novo Nordisk stock rose as much as 8%.
- The FDA plans to restrict ingredients used by compounding pharmacies.
- Official Wegovy and Ozempic are now available for as low as $199 through TrumpRx
Follow Inspirepreneur Magazine for the latest American news.
